Health Care [ 9/12 ] | Biotechnology [ 35/76 ]
NASDAQ | Common Stock
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.
Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.
The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors.
In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection.
Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH.
The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021.
Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
On October 10, 2024, Gritstone bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in theU. S.
Bankruptcy Court for the District of Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 24 | -0.16 Increased by +48.39% | -0.28 Increased by +42.86% |
| May 9, 24 | -0.34 Decreased by -13.33% | -0.32 Decreased by -6.25% |
| Mar 5, 24 | -0.26 Increased by +13.33% | -0.33 Increased by +21.21% |
| Nov 8, 23 | -0.33 Increased by +5.71% | -0.33 |
| Aug 9, 23 | -0.31 Increased by +8.82% | -0.35 Increased by +11.43% |
| May 11, 23 | -0.30 Increased by +11.76% | -0.33 Increased by +9.09% |
| Mar 9, 23 | -0.30 Increased by +18.92% | -0.34 Increased by +11.76% |
| Nov 3, 22 | -0.35 Increased by +2.78% | -0.40 Increased by +12.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 57.00 K Decreased by -85.75% | -23.40 M Increased by +33.64% | Decreased by -41.05 K% Decreased by -365.69% |
| Mar 31, 24 | 49.00 K Decreased by -90.96% | -40.38 M Decreased by -18.81% | Decreased by -82.42 K% Decreased by -1.21 K% |
| Dec 31, 23 | 29.00 K Decreased by -97.81% | -30.82 M Decreased by -0.51% | Decreased by -106.27 K% Decreased by -4.50 K% |
| Sep 30, 23 | 1.56 M Increased by +258.94% | -38.43 M Decreased by -27.88% | Decreased by -2.46 K% Increased by +64.37% |
| Jun 30, 23 | 400.00 K Decreased by -85.51% | -35.26 M Decreased by -20.70% | Decreased by -8.81 K% Decreased by -733.15% |
| Mar 31, 23 | 542.00 K Decreased by -88.58% | -33.99 M Decreased by -17.94% | Decreased by -6.27 K% Decreased by -932.50% |
| Dec 31, 22 | 1.33 M Decreased by -25.45% | -30.66 M Decreased by -3.00% | Decreased by -2.31 K% Decreased by -38.16% |
| Sep 30, 22 | 436.00 K Decreased by -81.84% | -30.05 M Decreased by -6.89% | Decreased by -6.89 K% Decreased by -488.62% |